Daniel McCarthy is a seasoned pharmaceutical and life sciences executive with nearly 25 years of experience advancing mental health care in Canada and globally. Originally from Newfoundland, Daniel has built a distinguished career defined by strategic leadership, successful product launches, and a deep commitment to improving outcomes for people living with mental illness.

Daniel most recently served as Vice President of the Neuroscience Business Unit and Business Development at Lundbeck Canada, where he led a national team and oversaw one of the company’s most successful specialty product launches worldwide. During his tenure, he established Lundbeck’s first national patient support program, championed innovative approaches to market access, and played a pivotal role in securing the first-ever positive CADTH recommendation for a branded antidepressant. His work has consistently strengthened access to mental health treatments across the country.

Earlier in his career, Daniel held global leadership roles at Lundbeck’s headquarters in Denmark, guiding commercial strategy and portfolio development for breakthrough therapies in Alzheimer’s disease, depression, schizophrenia, and stroke. His contributions have been recognized through multiple international awards for innovation, leadership, and impact.

A passionate advocate for mental health, Daniel has spent his career amplifying patient needs, shaping policy discussions, and driving equitable access to care. Outside of his professional work, he is an avid fitness enthusiast and lover of the outdoors, bringing the grounded perspective and resilience that come from his Newfoundland upbringing.

Daniel is honoured to join the Board of Directors of the Mood Disorders Society of Canada and looks forward to contributing his experience, energy, and advocacy to advance the organization’s mission.